Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Insulin signaling pathway | R-HSA-74752 | map04910 | fluphenazine | 3372 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | fluphenazine | 3372 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | fluphenazine | 3372 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | fluphenazine | 3372 | drug-path |
| Pancreatic cancer | R-HSA-9700206 | map05212 | fluphenazine | 3372 | drug-path |
| Cell cycle | R-HSA-1640170 | map04110 | fluphenazine | 3372 | drug-path |
| Prostate cancer | R-HSA-2990872 | map05215 | fluphenazine | 3372 | drug-path |
| Melanoma | Q9UHD0-PRO_0000015379 | map05218 | fluphenazine | 3372 | drug-path |
| Vibrio cholerae infection | R-HSA-9609646 | map05110 | fluphenazine | 3372 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | fluphenazine | 3372 | drug-path |
| Proteasome | R-HSA-68819 | map03050 | fluphenazine | 3372 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | fluphenazine | 3372 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | fluphenazine | 3372 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | fluphenazine | 3372 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | fluphenazine | 3372 | drug-path |
| Acute myeloid leukemia | R-HSA-9680350 | map05221 | fluphenazine | 3372 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | fluphenazine | 3372 | drug-path |
| Complement and coagulation cascades | R-HSA-114591 | map04610 | fluphenazine | 3372 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | dopamine | 681 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | deferoxamine | 5288674 | drug-path |